Leukinferon Protein

Human LeukinFeron is a combines preparation of natural cytokines involved in cellular reactions elimination of pathogen (antigen). Treatment with LeukinFeron results in a reduced frequency of side effects caused by prospidine therapy. Human LeukinFeron in the combined therapy of Kaposi's sarcoma leads to a considerable improvement of the initially abnormal levels of immunocompetent and phagocytizing cells. A single dose of Human LeukinFeron is prodced from 1million leukocytes isolated from doner's blood contains natural IFN-alpha 10,000IU and a complex of cytokines from the first phase of the immune response at their natural ratio, e.g., IL-6, IL-12, TNF-alpha, MIF and LIF.

LF activates expression of HLA-Dr antigens on Human immune effectors and improve immune recognition. LF provides the normalizing action on CD4/CD8 cells interaction and cytokine production by immunocompetent cells that is important for immunoreactivity. LF is applied for the treatment of many viral  diseases, bacterial infections, including sepsis, tuberculosis, chlamidial, mucoplasmic, herpetic infections and oncological diseases.

Small volumes of LeukinFeron protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS634866 is a protein targeting LeukinFeron. Also known as LeukinFeron (LF). Host: Leukocytes from donor's blood.